Anthem Biosciences IPO Allotment Status

Anthem Biosciences Limited, incorporated in 2006, is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization ("CRDMO") with fully integrated operations encompassing drug discovery, development, and manufacturing processes, serving diverse customers including innovative, emerging biotech firms and large pharmaceutical companies on a global scale, manufacturing specialized fermentation-based APIs including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars, engaging in manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules as of September 30, 2024, having 196 projects including 170 discovery projects, 132 early phase projects, 16 late phase projects, and 13 commercial manufacturing projects, serving over 425 customers in CRDMO and specialty ingredients businesses spanning more than 44 countries.

Anthem Biosciences IPO comes with a total issue size of ₹3,395.00 crore, comprising entirely an offer for sale of 5.96 crore shares. The IPO opened on July 14, 2025, and closed on July 16, 2025. The allotment for the Anthem Biosciences IPO is expected to be finalized on Thursday, July 17, 2025. The Anthem Biosciences share price is set at ₹570 per share (fixed price).

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check Anthem Biosciences IPO Allotment Status on Registrar Site

• Visit the Kfin Technologies Limited website 
• Select "Anthem Biosciences IPO" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check Anthem Biosciences IPO Allotment Status on BSE SME

• Navigate to the BSE IPO Allotment Status Page
• Choose "Anthem Biosciences IPO" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Anthem Biosciences IPO Subscription Status

Anthem Biosciences IPO received strong investor interest, being subscribed 67.42 times overall. The subscription showed excellent confidence across categories in the Anthem Biosciences stock price potential. Here is a category-wise breakdown of the subscription as of 4:59:33 PM on July 16, 2025:

• Retail Category: 5.98 times
• Non-Institutional Investors (NII): 44.70 times
• QIB Category: 192.80 times
• Employee Category: 6.99 times

Anthem Biosciences Share Price and Investment Details

The Anthem Biosciences stock price is set at ₹570 per share (fixed price) with a minimum lot size of 26 shares. The minimum investment required for retail investors is ₹14,820 for 1 lot (26 shares), while sNII investors need to invest a minimum of ₹2,07,480 for 14 lots (364 shares) and bNII investors need ₹10,07,760 for 68 lots (1,768 shares). The issue includes a reservation of up to 1,58,654 shares for employees offered at a discount of ₹50.00 to the issue price. Given the strong subscription response of 67.42 times overall, with QIB category being heavily oversubscribed at 192.80 times, NII at 44.70 times, while retail category showed moderate response at 5.98 times, the Anthem Biosciences share price is expected to list with good to significant premium.

Utilisation of IPO Proceeds

The Company will not receive any proceeds from the Offer and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.

Business Overview

The company operates in Contract Research, Development, and Manufacturing Organization having been in this business since 2006, serving as India's fastest growing CRDMO providing one-stop service across the drug life cycle for small molecules and biologics. Anthem Biosciences operates primarily in the CRDMO sector, providing innovation-focused approach enabling spectrum of technologically advanced solutions across modalities and manufacturing practices, specialized business model for small pharmaceutical and biotech companies from discovery to manufacturing, long-standing relationships with large, diversified and loyal customer base, and professional and experienced leadership team supported by qualified scientific talent pool with comprehensive capabilities spanning drug discovery, development, and manufacturing processes.